Treatment of AML with ELN Adverse-Risk Genetics (Complex Cytogenetics)
This protocol applies to patients with acute myeloid leukaemia classified in the ELN adverse-risk group — a population defined by complex cytogenetics and other poor-risk genetic aberrations, for whom a precisely structured induction strategy is required.
Clinical Scenario
The ELN adverse-risk group includes patients with acute myeloid leukaemia whose disease is characterised by complex cytogenetics and other poor-risk genetic aberrations. This genetic risk classification drives the choice of induction strategy and subsequent management planning.
Treatment Goal
The aim of induction is to achieve complete remission (CR) or complete remission with incomplete haematological recovery (CRi), defined as fewer than 5% blasts in the bone marrow. Response is assessed between day 14 and day 21 of induction.
Induction Approach — Partial Overview
Standard induction chemotherapy using a cytarabine-and-anthracycline backbone is recommended for this patient group. In eligible younger patients, additional chemotherapy agents may be incorporated into the induction regimen.
The complete protocol — including full regimen, eligibility criteria, sequencing, and consolidation pathway — is available via structured access below.
References
- The adverse-risk AML group includes patients with complex cytogenetics and other poor-risk genetic aberrations.
- In the remaining patients with ELN adverse risk, 7 + 3 ChT is recommended [II, A] with the option to add cladribine or fludarabine to induction ChT in patients up to 60 years (though cladribine and fludarabine are not approved for this indication) [II, C].
- After the first induction cycle, response should be assessed between day 14 and day 21.
- As soon as patients achieve CR/CRi after 1 or 2 induction cycles, they should proceed to consolidation treatment [II, B].
View source ↗